Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials
Open Access
- 22 October 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 33 (24) , 3078-3087
Abstract
The aim of this study was to evaluate benefits and risks of extending dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in the drug-eluting stent era. We searched electronic databases (Medline, EMBASE, the Cochrane Central Register of Controlled Trials), relevant websites, reference lists, conference abstracts, reviews, chapters in books, and proceedings of advisory panels for the US Food and Drug Administration, for randomized controlled trials investigating the clinical impact of extending DAPT duration in patients undergoing PCI. The primary endpoint was all-cause death. The secondary endpoints were myocardial infarction (MI), stent thrombosis (ST), cerebrovascular accidents (CVAs), and thrombolysis in myocardial infarction (TIMI) major bleeding. We included four trials that randomized 8231 patients (50.2%, extended DAPT duration vs. 49.8%, control duration). A total of 8158 patients (99.1%) were available for final analyses. The median DAPT duration was 16.8 vs. 6.2 months for the extended DAPT and control groups, respectively. At follow-up (median 16.8 months) extending DAPT duration did not reduce all-cause death [odds ratio (95% confidence interval) = 1.15 (0.85–1.54), P = 0.36], MI [0.95 (0.66–1.36), P = 0.77], ST [0.88 (0.43–1.81), P = 0.73], or CVAs [1.51 (0.92–2.47), P = 0.10]. Conversely, extended DAPT duration clearly increased the risk of TIMI major bleeding [2.64 (1.31–5.30), P = 0.006]. The extension of DAPT duration after percutaneous coronary interventions may increase the risk of bleeding without reducing ischaemic events. These results need corroboration from large ongoing trials.Keywords
This publication has 35 references indexed in Scilit:
- Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary StentingCirculation, 2012
- Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)European Heart Journal, 2010
- Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting StentsNew England Journal of Medicine, 2010
- Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysisBMJ, 2008
- A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery DiseaseJACC, 2007
- Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery StentsJACC, 2007
- Pathology of Drug-Eluting Stents in HumansJACC, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analysesBMJ, 2003
- Investigating and dealing with publication and other biases in meta-analysisBMJ, 2001